在慢性心力衰竭中Omecamtiv Mecarbil对运动能力的影响:METEORIC- HF随机临床试验
Gregory D Lewis1, Adriaan A Voors2, Alain Cohen-Solal3
1Division of Cardiology, Massachusetts General Hospital, Boston.
JAMA
|July 19, 2022
概括
在心力衰竭患者中,Omecamtiv mecarbil 没有改善运动能力. 这项研究表明它不是一种可行的治疗方法来改善HFrEF患者的身体功能.
科学领域:
- 心脏病学
- 药理学
- 临床试验
背景情况:
- 运动限制是心力衰竭的关键症状之一.
- 目前以指导方针为导向的医学疗法并不能持续改善HFrEF患者的运动能力.
- Omecamtiv mecarbil是一种新型的直接肌肉激活剂,用于改善心脏功能.
研究的目的:
- 评估omecamtiv mecarbil在慢性HFrEF患者中提高运动能力的有效性.
- 评估omecamtiv mecarbil对HFrEF运动能力和其他功能性措施的影响.
主要方法:
- 3期,双盲,安慰剂对照随机试验,包括276名HFrEF患者.
- 在20周内,患者每天口服两次omecamtiv mecarbil或安慰剂.
- 主要终点是从基线到第20周的最大氧气摄入量 (V· O2) 的变化.
主要成果:
- 在omecamtiv mecarbil和安慰剂组之间没有观察到峰值V·o2的平均变化.
- 峰值V·o2的最小平方平均差异为- 0. 45mL/ kg/ min (95% CI, - 1. 02至0. 13; P=13).
- 各组的不良反应一般相似,主要心脏不良事件没有显著增加.
结论:
- 在20周的治疗期间,Omecamtiv mecarbil没有显著改善慢性HFrEF患者的运动能力.
- 这些发现不支持使用omecamtiv mecarbil来改善HFrEF的运动能力.
- 可能需要进一步的研究来探索HFrEF运动限制的替代治疗策略.
更多相关视频
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.5K
14:26A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
Published on: April 7, 2014
15.6K
相关概念视频
Cardiomyopathy V: Interprofessional Care
30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Heart Failure Drugs: Inotropic Agents
708
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
708
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Exercise and Cardiac Output
1.3K
Regular physical activity is essential for maintaining cardiovascular health, with aerobic exercises being particularly effective. According to the American Heart Association, 150 minutes of moderate to intense aerobic exercise per week is recommended for a healthy heart. Aerobic activities may include brisk walking, running, bicycling, cross-country skiing, and swimming, ideally performed three to five times per week.
Sustained exercise increases the muscles' oxygen demand, which can be...
Sustained exercise increases the muscles' oxygen demand, which can be...
1.3K
Heart Failure II: Pathophysiology
31
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Heart Failure Drugs: β-Blockers
429
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
429
